Research Analysts Issue Forecasts for Natera FY2027 Earnings

Natera, Inc. (NASDAQ:NTRA) – Analysts at Leerink Partnrs issued their FY2027 earnings estimates for Natera in a research note issued on Friday, February 28th. Leerink Partnrs analyst P. Souda forecasts that the medical research company will post earnings of ($0.92) per share for the year. The consensus estimate for Natera’s current full-year earnings is ($1.49) per share.

NTRA has been the subject of several other research reports. Barclays began coverage on Natera in a research note on Thursday, January 23rd. They issued an “overweight” rating and a $200.00 target price for the company. Robert W. Baird upped their price objective on shares of Natera from $183.00 to $188.00 and gave the company an “outperform” rating in a research note on Friday. Guggenheim lifted their target price on shares of Natera from $170.00 to $200.00 and gave the stock a “buy” rating in a research report on Friday, January 17th. Canaccord Genuity Group reissued a “buy” rating and issued a $180.00 price target on shares of Natera in a research note on Wednesday, February 26th. Finally, The Goldman Sachs Group raised their price objective on Natera from $160.00 to $190.00 and gave the company a “buy” rating in a research note on Tuesday, January 28th. One investment analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $172.69.

Natera Price Performance

NTRA opened at $143.11 on Monday. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. The stock has a market capitalization of $18.89 billion, a P/E ratio of -81.31 and a beta of 1.66. The stock has a 50-day moving average price of $167.44 and a 200-day moving average price of $147.35. Natera has a 12-month low of $83.13 and a 12-month high of $183.00.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Thursday, February 27th. The medical research company reported ($0.41) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.01. The company had revenue of $476.10 million during the quarter, compared to the consensus estimate of $447.91 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%.

Insiders Place Their Bets

In other Natera news, CEO Steven Leonard Chapman sold 78,553 shares of the firm’s stock in a transaction dated Wednesday, January 22nd. The shares were sold at an average price of $164.97, for a total value of $12,958,888.41. Following the completion of the sale, the chief executive officer now directly owns 267,629 shares in the company, valued at $44,150,756.13. This trade represents a 22.69 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CFO Michael Burkes Brophy sold 25,931 shares of the company’s stock in a transaction that occurred on Wednesday, January 22nd. The stock was sold at an average price of $164.97, for a total value of $4,277,837.07. Following the transaction, the chief financial officer now owns 109,665 shares in the company, valued at $18,091,435.05. This trade represents a 19.12 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 208,299 shares of company stock worth $34,948,265. 7.60% of the stock is currently owned by company insiders.

Institutional Trading of Natera

Several institutional investors have recently bought and sold shares of NTRA. LRI Investments LLC bought a new position in shares of Natera during the fourth quarter valued at $29,000. Blue Trust Inc. raised its position in Natera by 104.3% in the 4th quarter. Blue Trust Inc. now owns 190 shares of the medical research company’s stock worth $30,000 after buying an additional 97 shares during the last quarter. Versant Capital Management Inc lifted its stake in Natera by 345.8% during the 4th quarter. Versant Capital Management Inc now owns 214 shares of the medical research company’s stock valued at $34,000 after acquiring an additional 166 shares during the period. Covestor Ltd lifted its stake in Natera by 34.3% during the 3rd quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock valued at $47,000 after acquiring an additional 95 shares during the period. Finally, EverSource Wealth Advisors LLC boosted its holdings in shares of Natera by 372.9% during the 4th quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company’s stock valued at $52,000 after acquiring an additional 261 shares during the last quarter. 99.90% of the stock is owned by hedge funds and other institutional investors.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.